Silence Therapeutics Plc has applied to the German regulator to bring its short-interfering RNA molecule (siRNA) for solid tumours into a first-in-man study. If approved, it would be the company’s first internal candidate in the clinic.
Silence Therapeutics Plc has applied to the German regulator to bring its short-interfering RNA molecule (siRNA) for solid tumours into a first-in-man study. If approved, it would be the company’s first internal candidate in the clinic.